Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 2/20 | 0.47 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.42 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.39 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CPA1 | P15085 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30852968 | 0.82 | LAP3 (0.44) | LAP3RNPEPSLC7A5FOLH1CACNA2D1 | |
| SCHEMBL13554081 | 0.81 | LAP3 (0.35) | LAP3RNPEPSLC7A5FOLH1CACNA2D1 | |
| SCHEMBL30497659 | 0.81 | SLC1A3 (0.41) | LAP3RNPEPSLC7A5FOLH1SLC1A3 | |
| SCHEMBL13554106 | 0.81 | LAP3 (0.35) | LAP3RNPEPSLC7A5FOLH1CACNA2D1 | |
| SCHEMBL12141288 | 0.79 | TSHR (0.46) | LAP3RNPEPSLC7A5FOLH1CACNA2D1 | |
| SCHEMBL13461523 | 0.78 | LAP3 (0.48) | LAP3RNPEPSLC7A5FOLH1CACNA2D1 | |
| SCHEMBL20276339 | 0.78 | OR51E2 (0.36) | LAP3RNPEPSLC7A5 | |
| SCHEMBL26940415 | 0.78 | SMN1; SMN2 (0.40) | LAP3RNPEPALDH1A1ADRA1ASLC1A3 | |
| SCHEMBL3206858 | 0.78 | SMN1; SMN2 (0.40) | LAP3RNPEPALDH1A1ADRA1ASLC1A3 | |
| SCHEMBL8072286 | 0.78 | LAP3 (0.48) | LAP3RNPEPSLC7A5FOLH1CACNA2D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399297-A1 | Novel Glutamine Analogs | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2023-12-14 | — | — | US | disclosed |
| US-20230399297-A1 | Novel Glutamine Analogs | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2023-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399297-A1 | Novel Glutamine Analogs | GLUL, GATD3, GLS | LAP3 770/4885RNPEP 2535/4885SLC7A5 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.